May 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manufacturing process to express a..
April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell cancer (MCC). In PODIUM-2..